vs
Bioventus Inc.（BVS）与Resolute Holdings Management, Inc.（RHLD）财务数据对比。点击上方公司名可切换其他公司
Bioventus Inc.的季度营收约是Resolute Holdings Management, Inc.的1.3倍（$157.9M vs $117.7M），Bioventus Inc.净利率更高（9.3% vs -1.5%，领先10.8%），Resolute Holdings Management, Inc.自由现金流更多（$189.2M vs $37.4M）
Bioventus Inc.是一家全球化医疗技术企业，专注于骨科生物制剂领域，研发并商业化促进骨关节愈合、肌肉骨骼疼痛管理及再生护理的相关产品，服务全球多地的骨科临床医师、康复师及患者群体。
Resolute Holdings Management, Inc.是一家澳大利亚矿业企业，核心业务布局于非洲地区，目前运营两座金矿，分别为位于马里的 Syama 金矿和塞内加尔的 Mako 金矿，专注于黄金资源的勘探、开采及相关运营管理工作。
BVS vs RHLD — 直观对比
营收规模更大
BVS
是对方的1.3倍
$117.7M
净利率更高
BVS
高出10.8%
-1.5%
自由现金流更多
RHLD
多$151.8M
$37.4M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $157.9M | $117.7M |
| 净利润 | $14.8M | $-1.7M |
| 毛利率 | 68.9% | 55.7% |
| 营业利润率 | 12.3% | 30.2% |
| 净利率 | 9.3% | -1.5% |
| 营收同比 | 2.8% | — |
| 净利润同比 | 3902.8% | — |
| 每股收益（稀释后） | $0.21 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BVSRHLD
| Q4 25 | $157.9M | $117.7M | ||
| Q3 25 | $138.7M | $120.9M | ||
| Q2 25 | $147.7M | $119.6M | ||
| Q1 25 | $123.9M | $103.9M | ||
| Q4 24 | $153.6M | — | ||
| Q3 24 | $139.0M | — | ||
| Q2 24 | $151.2M | — | ||
| Q1 24 | $129.5M | — |
净利润BVSRHLD
| Q4 25 | $14.8M | $-1.7M | ||
| Q3 25 | $3.2M | $-231.0K | ||
| Q2 25 | $7.5M | $-611.0K | ||
| Q1 25 | $-2.6M | $-3.4M | ||
| Q4 24 | $-388.0K | — | ||
| Q3 24 | $-5.2M | — | ||
| Q2 24 | $-25.7M | — | ||
| Q1 24 | $-4.9M | — |
毛利率BVSRHLD
| Q4 25 | 68.9% | 55.7% | ||
| Q3 25 | 68.0% | 59.0% | ||
| Q2 25 | 69.1% | 57.5% | ||
| Q1 25 | 67.0% | 52.5% | ||
| Q4 24 | 66.8% | — | ||
| Q3 24 | 67.3% | — | ||
| Q2 24 | 68.5% | — | ||
| Q1 24 | 68.3% | — |
营业利润率BVSRHLD
| Q4 25 | 12.3% | 30.2% | ||
| Q3 25 | 8.1% | 34.3% | ||
| Q2 25 | 12.4% | 34.0% | ||
| Q1 25 | 3.9% | 24.7% | ||
| Q4 24 | 5.0% | — | ||
| Q3 24 | 2.6% | — | ||
| Q2 24 | -20.8% | — | ||
| Q1 24 | 3.8% | — |
净利率BVSRHLD
| Q4 25 | 9.3% | -1.5% | ||
| Q3 25 | 2.3% | -0.2% | ||
| Q2 25 | 5.1% | -0.5% | ||
| Q1 25 | -2.1% | -3.2% | ||
| Q4 24 | -0.3% | — | ||
| Q3 24 | -3.7% | — | ||
| Q2 24 | -17.0% | — | ||
| Q1 24 | -3.8% | — |
每股收益（稀释后）BVSRHLD
| Q4 25 | $0.21 | $-0.20 | ||
| Q3 25 | $0.05 | $-0.03 | ||
| Q2 25 | $0.11 | $-0.07 | ||
| Q1 25 | $-0.04 | $-0.39 | ||
| Q4 24 | $0.00 | — | ||
| Q3 24 | $-0.08 | — | ||
| Q2 24 | $-0.40 | — | ||
| Q1 24 | $-0.08 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $51.2M | $205.5M |
| 总债务越低越好 | — | $169.8M |
| 股东权益账面价值 | $184.1M | $6.5M |
| 总资产 | $683.6M | $333.4M |
| 负债/权益比越低杠杆越低 | — | 26.03× |
8季度趋势，按日历期对齐
现金及短期投资BVSRHLD
| Q4 25 | $51.2M | $205.5M | ||
| Q3 25 | $42.2M | $148.0M | ||
| Q2 25 | $32.9M | $99.9M | ||
| Q1 25 | $22.8M | $71.0M | ||
| Q4 24 | $41.6M | — | ||
| Q3 24 | $43.1M | — | ||
| Q2 24 | $32.0M | — | ||
| Q1 24 | $25.2M | — |
总债务BVSRHLD
| Q4 25 | — | $169.8M | ||
| Q3 25 | — | $173.4M | ||
| Q2 25 | — | $177.1M | ||
| Q1 25 | — | $180.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BVSRHLD
| Q4 25 | $184.1M | $6.5M | ||
| Q3 25 | $166.1M | $10.8M | ||
| Q2 25 | $161.2M | $9.6M | ||
| Q1 25 | $148.1M | $8.9M | ||
| Q4 24 | $147.9M | — | ||
| Q3 24 | $148.7M | — | ||
| Q2 24 | $150.9M | — | ||
| Q1 24 | $171.3M | — |
总资产BVSRHLD
| Q4 25 | $683.6M | $333.4M | ||
| Q3 25 | $701.6M | $293.2M | ||
| Q2 25 | $706.8M | $253.3M | ||
| Q1 25 | $691.4M | $214.3M | ||
| Q4 24 | $728.0M | — | ||
| Q3 24 | $769.5M | — | ||
| Q2 24 | $792.2M | — | ||
| Q1 24 | $794.2M | — |
负债/权益比BVSRHLD
| Q4 25 | — | 26.03× | ||
| Q3 25 | — | 16.01× | ||
| Q2 25 | — | 18.42× | ||
| Q1 25 | — | 20.38× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $38.0M | $196.1M |
| 自由现金流经营现金流 - 资本支出 | $37.4M | $189.2M |
| 自由现金流率自由现金流/营收 | 23.7% | 160.8% |
| 资本支出强度资本支出/营收 | 0.4% | 5.8% |
| 现金转化率经营现金流/净利润 | 2.57× | — |
| 过去12个月自由现金流最近4个季度 | $72.1M | $313.2M |
8季度趋势，按日历期对齐
经营现金流BVSRHLD
| Q4 25 | $38.0M | $196.1M | ||
| Q3 25 | $30.1M | $59.6M | ||
| Q2 25 | $25.9M | $48.9M | ||
| Q1 25 | $-19.3M | $18.4M | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | $10.3M | — | ||
| Q2 24 | $15.2M | — | ||
| Q1 24 | $-6.0M | — |
自由现金流BVSRHLD
| Q4 25 | $37.4M | $189.2M | ||
| Q3 25 | $29.6M | $58.6M | ||
| Q2 25 | $25.3M | $47.5M | ||
| Q1 25 | $-20.2M | $17.8M | ||
| Q4 24 | $18.7M | — | ||
| Q3 24 | $10.3M | — | ||
| Q2 24 | $15.1M | — | ||
| Q1 24 | $-6.3M | — |
自由现金流率BVSRHLD
| Q4 25 | 23.7% | 160.8% | ||
| Q3 25 | 21.4% | 48.5% | ||
| Q2 25 | 17.1% | 39.7% | ||
| Q1 25 | -16.3% | 17.1% | ||
| Q4 24 | 12.2% | — | ||
| Q3 24 | 7.4% | — | ||
| Q2 24 | 10.0% | — | ||
| Q1 24 | -4.9% | — |
资本支出强度BVSRHLD
| Q4 25 | 0.4% | 5.8% | ||
| Q3 25 | 0.3% | 0.8% | ||
| Q2 25 | 0.5% | 1.2% | ||
| Q1 25 | 0.7% | 0.6% | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.2% | — |
现金转化率BVSRHLD
| Q4 25 | 2.57× | — | ||
| Q3 25 | 9.54× | — | ||
| Q2 25 | 3.48× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BVS
| Pain Treatments | $71.1M | 45% |
| Surgical Solutions | $48.9M | 31% |
| Restorative Therapies | $19.5M | 12% |
| Other | $18.4M | 12% |
RHLD
暂无分部数据
